Nicox S.A.
PAR: ALCOX.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gavin Spencer
- Employees
- 28
- Headquarters
- Valbonne, France
- IPO year
- 2000
- Market cap
- €27.4M
- Website
- https://www.nicox.com
Loading ALCOX…
Loading profile data…Frequently asked questions about ALCOX
What does Nicox S.A. (ALCOX.PA) do?
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which...
Where does ALCOX.PA trade?
Nicox S.A. (ALCOX.PA) trades on the Euronext Paris.
What sector is ALCOX.PA in?
Nicox S.A. (ALCOX.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nicox S.A.?
Gavin Spencer is the chief executive officer of Nicox S.A. (ALCOX.PA).
Where is Nicox S.A. headquartered?
Nicox S.A. is headquartered in France.
Does ALCOX.PA pay a dividend?
Nicox S.A. (ALCOX.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALCOX.PA go public?
Nicox S.A. (ALCOX.PA) completed its initial public offering in 2000.